Display options
Cite
Bayani J, Poncet C, Crozier C, et al. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. NPJ Breast Cancer. 2021;7(1):98doi: 10.1038/s41523-021-00301-0.
Bayani, J., Poncet, C., Crozier, C., Neven, A., Piper, T., Cunningham, C., Sobol, M., Aebi, S., Benstead, K., Bogler, O., Dal Lago, L., Fraser, J., Hilbers, F., Hedenfalk, I., Korde, L., Linderholm, B., Martens, J., Middleton, L., Murray, M., Kelly, C., Nilsson, C., Nowaczyk, M., Peeters, S., Peric, A., Porter, P., Schröder, C., Rubio, I. T., Ruddy, K. J., van Asperen, C., Van Den Weyngaert, D., van Deurzen, C., van Leeuwen-Stok, E., Vermeij, J., Winer, E., Giordano, S. H., Cardoso, F., & Bartlett, J. M. S. (2021). Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. NPJ breast cancer, 7(1), 98. https://doi.org/10.1038/s41523-021-00301-0
Bayani, Jane, et al. "Evaluation of multiple transcriptomic gene risk signatures in male breast cancer." NPJ breast cancer vol. 7,1 (2021): 98. doi: https://doi.org/10.1038/s41523-021-00301-0
Bayani J, Poncet C, Crozier C, Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hilbers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schröder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. NPJ Breast Cancer. 2021 Jul 26;7(1):98. doi: 10.1038/s41523-021-00301-0. PMID: 34312396; PMCID: PMC8313692.
Copy Download .nbib Format: NLM
Share it on

NPJ Breast Cancer. 2021 Jul 26;7(1):98. doi: 10.1038/s41523-021-00301-0.

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.

NPJ breast cancer

Jane Bayani, Coralie Poncet, Cheryl Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schröder, Isabel T Rubio, Kathryn J Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Sharon H Giordano, Fatima Cardoso, John M S Bartlett

Affiliations

  1. Ontario Institute for Cancer Research, Toronto, ON, Canada.
  2. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  3. Department of Statistics, European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  4. University of Edinburgh, Scotland, UK.
  5. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
  6. Department of Oncology, Cheltenham General Hospital, Cheltenham, UK.
  7. Global Academic Programs, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  8. Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium.
  9. Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK.
  10. Breast International Group, Brussels, Belgium.
  11. Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.
  12. University of Washington, Seattle, WA, USA.
  13. Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  14. Medical Oncology, Erasmus Medical Center Rotterdam; BOOG, Rotterdam, The Netherlands.
  15. Department Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  16. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  17. All Ireland Cooperative Oncology Research Group (ICORG), Dublin, Ireland.
  18. Department of Oncology, Västmanlands Hospital, Västerås, Sweden.
  19. Specialist Hospital. St. Wojciech, Gdansk, Poland.
  20. Department of Radiation Oncology Maastro, Masstricht, The Netherlands.
  21. Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center & Department of Pathology, University of Washington, Seattle, WA, USA.
  22. Department Medical Oncology, University Medical Center Groningen; BOOG, Groningen, The Netherlands.
  23. Breast Surgical Unit. Hospital Universitario Vall d´Hebron, Barcelona, Spain.
  24. Mayo Clinic, Department of Oncology, Rochester, MN, USA.
  25. Department of Clinical Genetics, Leiden University Medical Center; BOOG, Leiden, The Netherlands.
  26. Department of Radiotherapy, ZNA Middelheim, Antwerpen, Belgium.
  27. Department Pathology, Erasmus Medical Center; BOOG, Rotterdam, The Netherlands.
  28. Dutch Breast Cancer Research Group (BOOG), Amsterdam, The Netherlands.
  29. Department of Medical Oncology, ZNA Jan Palfijn, Merksem, Belgium.
  30. Dana-Farber Cancer Institute, Boston, MA, USA.
  31. University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  32. Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation; EORTC, Lisbon, Portugal.
  33. Ontario Institute for Cancer Research, Toronto, ON, Canada. [email protected].
  34. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. [email protected].
  35. University of Edinburgh, Scotland, UK. [email protected].

PMID: 34312396 PMCID: PMC8313692 DOI: 10.1038/s41523-021-00301-0

Abstract

Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.

© 2021. The Author(s).

References

  1. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  2. J Clin Oncol. 2010 Apr 20;28(12):2114-22 - PubMed
  3. J Clin Oncol. 2006 Aug 10;24(23):3726-34 - PubMed
  4. J Clin Oncol. 2011 Nov 10;29(32):4273-8 - PubMed
  5. N Engl J Med. 2016 Aug 25;375(8):717-29 - PubMed
  6. N Engl J Med. 2018 Jul 12;379(2):111-121 - PubMed
  7. Breast Cancer Res Treat. 2019 Jul;176(2):377-386 - PubMed
  8. Steroids. 2011 Jul;76(8):777-80 - PubMed
  9. Clin Cancer Res. 2010 Nov 1;16(21):5222-32 - PubMed
  10. Nat Genet. 2002 May;31(1):55-9 - PubMed
  11. Expert Opin Pharmacother. 2007 Feb;8(2):193-202 - PubMed
  12. PLoS One. 2020 Sep 3;15(9):e0238593 - PubMed
  13. Cancer. 2004 Jul 1;101(1):51-7 - PubMed
  14. J Clin Oncol. 2004 Feb 15;22(4):735-42 - PubMed
  15. JAMA Oncol. 2018 Apr 1;4(4):545-553 - PubMed
  16. Clin Cancer Res. 2012 Aug 15;18(16):4465-72 - PubMed
  17. Front Med (Lausanne). 2018 Sep 04;5:248 - PubMed
  18. Ann Oncol. 2014 Oct;25(10):1871-1888 - PubMed
  19. Nature. 2002 Jan 31;415(6871):530-6 - PubMed
  20. Mod Pathol. 2018 Feb;31(2):299-306 - PubMed
  21. Stat Med. 2013 Dec 30;32(30):5381-97 - PubMed
  22. J Clin Oncol. 2020 Jun 1;38(16):1849-1863 - PubMed
  23. Clin Cancer Res. 2020 Jan 1;26(1):101-109 - PubMed
  24. Ann Oncol. 2018 Feb 1;29(2):405-417 - PubMed
  25. N Engl J Med. 2019 Jun 20;380(25):2395-2405 - PubMed
  26. N Engl J Med. 2018 Oct 04;379(14):1385-1386 - PubMed
  27. J Clin Oncol. 2010 Jan 10;28(2):232-9 - PubMed
  28. J Natl Cancer Inst. 2016 Apr 29;108(9): - PubMed
  29. N Engl J Med. 2002 Dec 19;347(25):1999-2009 - PubMed
  30. NPJ Breast Cancer. 2017 Feb 15;3:3 - PubMed
  31. J Clin Oncol. 2008 Dec 1;26(34):5638-44 - PubMed
  32. Acta Oncol. 2001;40(4):467-71 - PubMed
  33. Clin Cancer Res. 2008 May 1;14(9):2601-8 - PubMed
  34. J Clin Oncol. 2018 May 10;36(14):1396-1404 - PubMed

Publication Types